Flubendazole Pharma Grade API is a benzimidazole carbamate derivative supplied for the manufacture of tablet, capsule, granule, oral suspension, and injectable suspension dosage forms. The compound is identified by CAS number 31430-15-6, has the molecular formula C16H12FN3O3, and a molar mass of 313.29 g/mol. The API is produced as a white to almost white crystalline powder with controlled polymorphic purity. Solid-state identity is confirmed by X-ray powder diffraction and differential scanning calorimetry against the approved reference standard. The manufacturing process is conducted under ICH Q7 GMP conditions, and the drug master file is maintained in the common technical document format. Bulk material is released after evaluation of assay, related substances, residual solvents, water content, residue on ignition, particle size distribution, bulk density, tapped density, and microbial limits. The product is intended for use by finished-dose manufacturers equipped with high-shear granulators, twin-shell blenders, roller compactors, capsule filling machines, and aseptic filling lines for injectable suspensions.

What Limits Direct Compression Performance of Flubendazole API?

The oral solid dosage grade is differentiated by particle size because direct compression of flubendazole is constrained by poor flow and segregation tendency with common fillers. The milled grade is controlled to a D90 of 20 µm or less by laser diffraction according to ISO 13320:2020. Bulk density of the oral solid dosage grade is typically 0.25 g/mL to 0.45 g/mL, and tapped density is typically 0.40 g/mL to 0.75 g/mL when measured according to Ph. Eur. 2.9.34. Direct compression formulations using this grade generally require addition of colloidal silicon dioxide at 0.5 % w/w to 1.0 % w/w and microcrystalline cellulose as a diluent to achieve acceptable flow. Without these adjustments, powder flow through a tablet press shoe can be non-uniform, causing weight variation above 2 % relative standard deviation on rotary tablet presses operating above 50 rpm.

Roller compaction of flubendazole is used when dry granulation is required. The cohesive nature of the milled grade can produce ribbons with variable density if the roll pressure is not tightly controlled. A roll pressure of 4 MPa to 6 MPa and roll speed of 2 rpm to 4 rpm are typical starting parameters for flubendazole blends containing 20 % w/w to 30 % w/w API on a roller compactor with 250 mm rolls. Ribbons are milled through a 1.0 mm screen and blended with extragranular disintegrant before compression. The compacted granules have improved flow but reduced compactibility; therefore, tablet hardness is often lower than that achieved by wet granulation. This trade-off is evaluated by tensile strength testing according to USP <1217>.

Because flubendazole is described in a pharmacopoeial monograph in some jurisdictions but not harmonized across all compendia, the API is controlled against internal specifications that incorporate the general chapters of the current European Pharmacopoeia and United States Pharmacopeia where applicable. Certificate of analysis includes identification by infrared absorption spectrophotometry using the KBr pellet technique, retention time comparison by HPLC, and UV absorbance spectrum. Assay by liquid chromatography is specified between 98.0 % and 102.0 % on the dried basis using Ph. Eur. 2.2.29. Total related substances are limited to 1.0 %, with any unspecified impurity limited to 0.10 %. Water content determined by Karl Fischer titration is limited to 0.5 % using Ph. Eur. 2.5.12. Residue on ignition is limited to 0.1 % using Ph. Eur. 2.4.14. Residual solvents are controlled according to ICH Q3C; for a synthetic route using methanol and dichloromethane, methanol is limited to 3000 ppm and dichloromethane to 600 ppm. Elemental impurities are controlled according to ICH Q3D with test data reported for Class 1, Class 2A, and Class 2B elements.

For the injectable grade, bacterial endotoxin limits are established per Ph. Eur. 2.6.14 and are calculated from the maximum daily dose; a limit of 0.05 EU/mg is representative when the intended dose exceeds 100 mg/day. The sterile grade is also tested for particulate matter according to Ph. Eur. 2.9.19 and for sterility according to Ph. Eur. 2.6.1 after the finished suspension is manufactured.

Differences From Other Benzimidazole Carbamates in Oral and Injectable Formulation

Flubendazole differs from mebendazole by the presence of a para-fluoro substituent on the benzoyl ring, which alters the electron-withdrawing character of the carbonyl system and the solid-state solubility of the API. Compared with albendazole, flubendazole does not rely on oxidation to an active sulfoxide metabolite; the parent benzimidazole carbamate is the primary active moiety. This distinction matters in injectable formulation because the low aqueous solubility of flubendazole requires particle size reduction to a D90 of 5 µm or smaller for suspension syringeability, whereas albendazole injection development has focused on the sulfoxide metabolite rather than the parent. In oral dosage forms, flubendazole has lower systemic absorption than albendazole, which is consistent with its use in gastrointestinal helminth infections in veterinary medicine. Dissolution comparisons are typically performed with USP Apparatus 2 at 50 rpm in 900 mL of 0.1 M HCl containing 0.1 % sodium lauryl sulfate to distinguish formulation performance. The fluorinated analogue also shows reduced cytochrome P450-mediated metabolic clearance in some in vitro models, but no bioequivalence should be extrapolated from these data alone.

In veterinary use, flubendazole API is formulated into oral granules and feed premixes for swine and poultry. Published target species include pigs for gastrointestinal nematodes such as Ascaris suum and Trichuris suis, and poultry for Ascaridia galli and Heterakis gallinarum. The injectable suspension grade is used in investigational filarial disease programs but is not a routine human pharmaceutical in all jurisdictions. This regulatory status must be confirmed by the finished-dose manufacturer for each market.

In comparative dissolution studies, flubendazole oral tablets may exhibit slower release in 0.1 M HCl than mebendazole tablets because of the higher crystallinity of the fluorinated analogue. However, this difference is formulation-dependent and should be evaluated with the intended manufacturing process. The absence of a thioether substituent, as found in albendazole and fenbendazole, means that sulfur-related impurities such as albendazole sulfoxide are not present in flubendazole release testing. This simplifies the related substances profile but does not eliminate the need for control of hydrolytic degradation products.

When Injectable Suspension Manufacture Requires Wet Milling Under Aseptic Conditions

The injectable suspension grade of flubendazole is wet-milled to a D90 of 5 µm or smaller in an aqueous vehicle containing a non-ionic stabilizer such as polysorbate 80 or poloxamer 188. Milling is performed with a high-shear rotor-stator mill followed by a bead mill; the milling chamber temperature is maintained below 25 °C to avoid polymorphic conversion and particle aggregation. Terminal sterilization by moist heat is not always feasible because the suspension can undergo particle growth at autoclave temperatures of 121 °C for 15 min; therefore, aseptic filtration of the vehicle and gamma irradiation of the API may be used as alternative microbial control measures. Bacterial endotoxin limits are calculated from the maximum daily dose and are typically lower than 0.05 EU/mg when the intended dose exceeds 100 mg per day. The final suspension is tested for viscosity with a rotational viscometer and for syringeability through a 21-gauge needle. A viscosity range of 10 mPa·s to 100 mPa·s is commonly targeted for injectable suspensions, but published data for flubendazole-specific injectable products is limited.

Wet granulation of flubendazole oral grades is typically performed in a high-shear granulator with an impeller speed of 300 rpm and a chopper speed of 1500 rpm. The binder solution is added at a rate of 10 g/min per kilogram of dry blend until an end-point torque of 2 N·m to 4 N·m is reached. Granules are dried in a fluid-bed dryer at an inlet air temperature of 50 °C to 60 °C until the loss on drying is below 2 %. Drying above 70 °C is avoided because the carbamate moiety can undergo hydrolytic degradation in the presence of residual moisture. The dried granules are milled through a 1.0 mm screen and blended with magnesium stearate at 0.5 % w/w for compression. Capsule filling of the direct-compression grade is performed on a dosator-type capsule machine; the powder bed height is maintained to minimize tamping force variation.

Granule grades for medicated feed premixes are produced by wet granulation of the API with lactose monohydrate and maize starch, followed by drying and sizing through a 1.5 mm screen. The granule form reduces dusting and improves uniformity in final feed mixing. Segregation testing according to ASTM D6940-20 or equivalent is used to confirm blend uniformity during pneumatic conveying. Feed premix concentrations are adjusted by the finished-dose manufacturer to meet regional maximum residue limits for edible tissues; no single concentration applies across all species.

Flubendazole should not be dry-blended with highly alkaline excipients such as sodium bicarbonate or with strong oxidizing agents, because the carbamate group is susceptible to base-catalyzed hydrolysis. It is compatible with lactose monohydrate, maize starch, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate when the water content is controlled below 0.5 %.

Industrial hygiene controls for flubendazole powder handling include local exhaust ventilation and containment systems capable of maintaining airborne dust below the applicable occupational exposure limit for the facility. Because a substance-specific limit may not be published in all jurisdictions, many manufacturers use a total inhalable dust limit of 3 mg/m³ as a default, but this is not a product-specific standard. Cross-contamination control is verified by cleaning validation using swab and rinse sampling with an HPLC limit of detection not exceeding 10 ppm of the next product.

The API is stored at 15 °C to 25 °C in tightly closed containers protected from light. The retest interval is 24 months when the container is unopened and stored under the specified conditions. Opened containers should be used within 6 months if re-sealed under nitrogen.